Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Change in Account Payables (2019 - 2026)

Atea Pharmaceuticals' Change in Account Payables history spans 8 years, with the latest figure at -$3.5 million for Q1 2026.

  • Quarterly Change in Account Payables fell 219.46% to -$3.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Mar 2026, up 114.97% year-over-year, with the annual reading at $8.5 million for FY2025, 4019.9% up from the prior year.
  • Change in Account Payables came in at -$3.5 million for Q1 2026, down from $9.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $16.9 million in Q1 2024 to a low of -$15.7 million in Q2 2024.
  • The 5-year median for Change in Account Payables is $315000.0 (2024), against an average of $288941.2.
  • Year-over-year, Change in Account Payables soared 1012.21% in 2024 and then crashed 1791.75% in 2025.
  • Atea Pharmaceuticals' Change in Account Payables stood at $1.4 million in 2022, then soared by 169.16% to $3.9 million in 2023, then tumbled by 134.4% to -$1.3 million in 2024, then soared by 810.63% to $9.4 million in 2025, then plummeted by 137.1% to -$3.5 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Change in Account Payables are -$3.5 million (Q1 2026), $9.4 million (Q4 2025), and -$5.3 million (Q3 2025).